| Ask Questions (ASQ):Implementation of a Communication Intervention (NCT05025748) | Barbara Ann Karmanos Cancer Institute | 2021-08-25 |
| Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (NCT03749850) | UMC Utrecht | 2021-03-01 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (NCT04670445) | Massachusetts General Hospital | 2021-01-23 |
| Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients (NCT05229575) | Campus Bio-Medico University | 2020-07-10 |
| Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients (NCT04199520) | Henan Cancer Hospital | 2020-04-15 |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites (NCT04267575) | Jerome Canady, M.D. | 2019-07-30 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (NCT03971409) | Laura Huppert, MD, BA | 2019-07-08 |
| Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide (NCT06361264) | KARANAHAN | 2018-11-01 |
| Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer (NCT04113096) | The University of The West Indies | 2018-10-01 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer (NCT03566485) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer (NCT03455270) | G1 Therapeutics, Inc. | 2018-05-09 |
| Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer (NCT03683147) | Roswell Park Cancer Institute | 2017-12-13 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners (NCT03112668) | Rutgers, The State University of New Jersey | 2017-12-06 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer (NCT03364348) | George W. Sledge Jr. | 2017-10-30 |
| Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (NCT03070002) | Northwestern University | 2017-10-19 |
| Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (NCT02892734) | Northwestern University | 2017-09-18 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (NCT03213041) | Northwestern University | 2017-09-14 |
| Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer (NCT03206203) | Vanderbilt-Ingram Cancer Center | 2017-08-29 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (NCT03128619) | Jonsson Comprehensive Cancer Center | 2017-08-02 |
| Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (NCT02860000) | Mayo Clinic | 2017-07-06 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery (NCT03044730) | Northwestern University | 2017-05-25 |
| Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer (NCT03139435) | Wake Forest University Health Sciences | 2017-05-11 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (NCT02897375) | Emory University | 2016-10-24 |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) (NCT02728596) | SWOG Cancer Research Network | 2016-10-07 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis (NCT02774681) | Northwestern University | 2016-08-31 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (NCT02824575) | Montefiore Medical Center | 2016-07-01 |
| Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab (NCT00194714) | University of Washington | 2016-05-01 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (NCT02648477) | City of Hope Medical Center | 2016-03-28 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (NCT02672475) | Vanderbilt-Ingram Cancer Center | 2016-03-01 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (NCT02536794) | Northwestern University | 2016-01-14 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy (NCT02599194) | Andrei Iagaru | 2015-07-01 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (NCT02457910) | Vanderbilt-Ingram Cancer Center | 2015-06-01 |
| Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer (NCT02157051) | University of Washington | 2015-06-01 |
| Oxaliplatin in Treating Patients With Metastatic Breast Cancer (NCT02077998) | University of California, Davis | 2015-05-01 |
| Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer (NCT02331212) | Wake Forest University Health Sciences | 2015-03-01 |
| Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276) | City of Hope Medical Center | 2015-01-07 |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT02219789) | Mayo Clinic | 2014-12-05 |
| Phase II Study of Everolimus Beyond Progression (NCT02269670) | Emory University | 2014-11-25 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (NCT02015559) | Jonsson Comprehensive Cancer Center | 2014-10-08 |
| Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (NCT02120469) | City of Hope Medical Center | 2014-10-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer (NCT02206334) | NRG Oncology | 2014-08-01 |
| Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung (NCT01741597) | City of Hope Medical Center | 2014-07-01 |
| BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer (NCT03603197) | Meabco A/S | 2014-06-05 |
| Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery (NCT01816035) | University of Washington | 2014-06-01 |
| BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx (NCT02038010) | Northwestern University | 2014-05-21 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (NCT01938833) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-04-01 |
| Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (NCT01922921) | University of Washington | 2014-02-05 |
| BP-C1 in Metastatic Breast Cancer Patients (NCT01861509) | Meabco A/S | 2014-01-19 |
| Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (NCT01908101) | University of Washington | 2014-01-08 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer (NCT01349088) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-12-01 |
| Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy (NCT01941784) | Wake Forest University Health Sciences | 2013-11-25 |
| PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer (NCT01712815) | University of Southern California | 2013-11-22 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT02046421) | University of Chicago | 2013-11-01 |
| Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer (NCT01986569) | Asan Medical Center | 2013-11-01 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection (NCT01249443) | AIDS Malignancy Consortium | 2013-11-01 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (NCT01918306) | Vanderbilt-Ingram Cancer Center | 2013-09-01 |
| Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer (NCT01873833) | University of Southern California | 2013-07-29 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (NCT01730833) | City of Hope Medical Center | 2013-07-17 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (NCT01783756) | Jonsson Comprehensive Cancer Center | 2013-06-26 |
| Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer (NCT01897441) | Albert Einstein College of Medicine | 2013-06-01 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (NCT01791478) | Vanderbilt-Ingram Cancer Center | 2013-04-01 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675) | Sanjiv Sam Gambhir | 2013-03-04 |
| BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment (NCT03789019) | Meabco A/S | 2013-02-22 |
| Cabergoline in Metastatic Breast Cancer (NCT01730729) | Northwestern University | 2013-02-11 |
| BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer (NCT02783794) | Meabco A/S | 2012-12-24 |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases (NCT01939483) | University of California, Irvine | 2012-12-01 |
| Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer (NCT01729884) | University of Washington | 2012-12-01 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (NCT01720602) | University of Washington | 2012-11-01 |
| Phase I: At-Home Support for Rural Women Using Group Video Calling (NCT01672684) | Stanford University | 2012-10-01 |
| Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer (NCT02370264) | University of Southern California | 2012-10-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer (NCT01219907) | University of Washington | 2012-06-01 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT01575522) | National Cancer Institute (NCI) | 2012-03-01 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (NCT01697293) | Prescient Therapeutics, Ltd. | 2012-01-01 |
| BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (NCT01339442) | Washington University School of Medicine | 2011-11-14 |
| Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (NCT01355393) | University of Washington | 2011-07-01 |
| Vaccination of High Risk Breast Cancer Patients (NCT01390064) | University of Arkansas | 2011-07-01 |
| Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer (NCT01242800) | Eastern Cooperative Oncology Group | 2011-05-16 |
| Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer (NCT00992602) | University of Washington | 2011-04-01 |
| Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer (NCT01093612) | City of Hope Medical Center | 2011-03-16 |
| Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer (NCT01277757) | National Cancer Institute (NCI) | 2011-03-01 |
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891) | University of Alabama at Birmingham | 2011-03-01 |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer (NCT01385280) | University of Arizona | 2011-02-01 |
| Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer (NCT01729832) | Ohio State University Comprehensive Cancer Center | 2011-01-10 |
| Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer (NCT01124695) | ECOG-ACRIN Cancer Research Group | 2011-01-07 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer (NCT01263145) | National Cancer Institute (NCI) | 2011-01-05 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01288261) | University of Arizona | 2011-01-01 |
| Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery (NCT01292083) | University of Southern California | 2011-01-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel (NCT01243541) | Northwestern University | 2010-11-03 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (NCT01153672) | University of Washington | 2010-11-01 |